Award search
Awards for “MOLECULAR EXPRESS, INC”
13 awards on this page · sorted by amount · page 1
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| 75N93024C00017 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $3M | 2024-09-01 | 2027-08-31 | 541714 | VESIVAX TLR7 FORMULA |
| 75N93021C00027 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $2.29M | 2021-07-01 | 2024-07-31 | 541715 | THE CONTRACTOR SHALL TO EVALUATE THE DIFFERENT CO-DELIVERY METHODS OF A MODEL HIV ANTIGEN USING THE VESIVAX LIPOSOMAL PLATFORM. |
| 75N93024C00018 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $2M | 2024-07-01 | 2026-08-31 | 541715 | DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS |
| 75N93019C00007 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $599.98K | 2019-05-31 | 2021-05-30 | 541715 | THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AN EFFECTIVE HIV VACCINE BY EXPLORING CO-DELIVERY FORMULATIONS OF HIVANTIGENS AND ADJUVANTS. |
| 75N93023C00033 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $599.93K | 2023-09-30 | 2025-04-10 | 541715 | DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151. |
| 75N93021C00039 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $569.81K | 2021-08-01 | 2023-07-31 | 541715 | DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION |
| HHSN272201600032C | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $440.93K | 2016-08-26 | 2018-08-29 | 541711 | IGF::OT::IGF SELECTION OF VESIVAX VACCINE FOR WEST NILE VIRUS |
| 75N93022C00012 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $300K | 2022-07-01 | 2023-08-31 | 541715 | THE CONTRACTOR SHALL TO ENGINEER NOVEL HIV GP41 ECTODOMAIN ANTIGENS (HIV GP41E-HD) FOR THE INCORPORATION INTO THE IMMUNOGENIC VESIVAX FORMULATIONS. |
| 75N93020C00012 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $299.99K | 2020-06-01 | 2022-07-31 | 541715 | THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A VESIVAX PLATFORM-BASED LIPOSOMAL FORMULATION THAT WILL EFFICIENTLY DISPLAY THE HIV IMMUNOGEN. |
| 75N93020C00010 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $299.96K | 2020-06-01 | 2022-05-31 | 541715 | THE OBJECTIVE OF THIS CONTRACT IS TO IDENTIFY A POTENTIAL HIV ANTIGEN-CONJUGATED VACCINE FORMULATION BY EXPLORING CO-DELIVERY OF HIV ANTIGENS AND ADJUVANT MOLECULES. |
| HHSN272201700081C | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $296.29K | 2017-07-27 | 2018-10-31 | 541711 | IGF::OT::IGF DELIVERY OF SELF-REPLICATING HIV VACCINES USING IN VITRO RECONSTITUTED VIRUS-LIKE PARTICLES |
| HHSN261201100068C | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $197.67K | 2011-09-15 | 2012-06-14 | 541711 | DEVELOPMENT OF A COMMERCIAL POINT-OF-CARE DEVICE CAPABLE OF ELECTRONICALLY SENSING TUMOR CELLS AND MOLECULAR CANCER BIOMARKERS IN THE CIRCULATING PERIPHERAL BLOOD BASED PANEL ON THE MOLECULAR DIFFERENCES BETWEEN THE SURFACES OR NORMAL AND CANCER CELL OF A PATIENT. |
| 75N93018C00053 | MOLECULAR EXPRESS, INC | Department of Health and Human Services | $193.94K | 2018-09-17 | 2023-07-01 | 541714 | PURPOSE: CONTRACT AWARD FOR SBIR TOPIC 061 "MUCOSAL STIMULATORY VESIVAX VACCINES AGAINST ENTERIC INFECTIONS" IN THE AMOUNT OF $213,800. |